India, May 30 -- Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that Itepekimab met the primary endpoint in one of two trials of chronic obstructive pulmonary disease or COPD, while the second trial failed to meet the main goal.
The companies said they are reviewing the trial data and will discuss with regulatory authorities to evaluate next steps.
A Phase 3 trial, AERIFY-1, evaluating the investigational use of itepekimab in adults who were former smokers with inadequately controlled COPD met the primary endpoint of significantly reducing moderate or severe acute exacerbations by 27% compared to placebo at week 52, a clinically meaningful benefit.
Meanwhile, a second Phase 3 trial, A...